Advances in the treatment of HIV disease have produced dramatic reductions in AIDS-related morbidity and mortality in the United States and Europe. However, despite lower drug prices and an increased focus on the global HIV epidemic, severe resource constraints in Africa, Asia and less developed countries throughout the world have limited the availability of antiretroviral therapy and opportunistic infection prophylaxis. With a distinguished track record of analysis and policy impact in the United States and Europe, we propose to build on over 10 years of experience examining the clinical impact, cost and cost-effectiveness of alternative HIV care strategies and expand efforts to three less developed countries. We propose the following aims: ? 1. To develop the Global AIDS Policy Model, a comprehensive and flexible state-transition model of the natural history and treatment of HIV disease in less developed countries. ? 2. To analyze data on HIV natural history, treatment efficacy, costs, and quality of life in each of 3 countries: Cote d'Ivoire, India, and South Africa. ? 3. To assess the clinical impact, cost, and cost-effectiveness of different strategies for antiretroviral therapy, opportunistic infection prophylaxis, and tuberculosis preventive therapy. In accordance with key areas of NIAID interest, these aims will help to develop practical and affordable methods for HIV treatment and inform the rational use of therapy in resource-diverse settings. The products of this proposal will investigate pressing HIV clinical and policy questions in each of these countries, and results will be provided to clinicians delivering care and to health officials responsible for shaping policy. Having already influenced HIV policy in the US through model-based cost-effectiveness analysis, the Global AIDS Policy Model team will formally address resource limitations for HIV care in these representative less developed countries. This project will elucidate questions of optimal HIV management for clinicians, public health officials, and policy makers, and it will provide a durable tool with which to address crucial questions in these countries and in other settings worldwide. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI058736-01A1
Application #
6842544
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Huebner, Robin E
Project Start
2004-07-01
Project End
2008-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
1
Fiscal Year
2004
Total Cost
$1,118,963
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Luz, Paula M; Osher, Benjamin; Grinsztejn, Beatriz et al. (2018) The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. J Int AIDS Soc 21:e25096
Neilan, Anne M; Cohn, Jennifer E; Lemaire, Jean-Francois et al. (2018) HIV Testing After a First Positive Rapid Diagnostic Test: A Role for Nucleic Acid Testing? Open Forum Infect Dis 5:ofy170
Freedberg, Kenneth A; Kumarasamy, Nagalingeswaran; Borre, Ethan D et al. (2018) Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India. AIDS Res Hum Retroviruses 34:486-497
Mallampati, Divya; MacLean, Rachel L; Shapiro, Roger et al. (2018) Optimal breastfeeding durations for HIV-exposed infants: the impact of maternal ART use, infant mortality and replacement feeding risk. J Int AIDS Soc 21:e25107
Zheng, Amy; Kumarasamy, Nagalingeswaran; Huang, Mingshu et al. (2018) The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. J Int AIDS Soc 21:e25085
Ahonkhai, Aimalohi A; Banigbe, Bolanle; Adeola, Juliet et al. (2018) High Medication Possession Ratios Associated With Greater Risk of Virologic Failure Among Youth Compared With Adults in a Nigerian Cohort. J Acquir Immune Defic Syndr 78:322-328
Kubiak, R W; Herbeck, J T; Coleman, S M et al. (2018) Urinary LAM grade, culture positivity, and mortality among HIV-infected South African out-patients. Int J Tuberc Lung Dis 22:1366-1373
Walensky, Rochelle P; Borre, Ethan D; Bekker, Linda-Gail et al. (2017) Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. Ann Intern Med 167:618-629
Hyle, Emily P; Jani, Ilesh V; Rosettie, Katherine L et al. (2017) The value of point-of-Care CD4 and Laboratory viral Load in tailoring ART monitoring Strategies to resource limitations. AIDS :
McCormick, Alethea W; Abuelezam, Nadia N; Fussell, Thomas et al. (2017) Displacement of sexual partnerships in trials of sexual behavior interventions: A model-based assessment of consequences. Epidemics 20:94-101

Showing the most recent 10 out of 223 publications